Specifies additional circumstances under which a patient shall be granted an exception to a step therapy protocol required by a health carrier for coverage of a prescription drug
Impact
This bill carries significant implications for patients requiring timely access to medically necessary drugs. By legislating that exceptions to step therapy protocols can be granted under certain conditions—such as a lack of efficacy in prior treatments or the potential for adverse effects—the bill seeks to enhance patient care and ensure that individuals receive appropriate medications based on their unique health needs. It may ultimately lead to greater accountability for health carriers and a more responsive healthcare system.
Summary
Senate Bill 959 seeks to amend existing laws regarding insurance coverage for prescription drugs, specifically focusing on the step therapy protocols employed by health carriers and benefit plans. The bill aims to establish a clearer process for patients and healthcare providers to request exceptions to standard step therapy requirements. Under the proposed legislation, patients will have access to a well-defined procedure to apply for a step therapy override exception, thus ensuring they are not forced to endure ineffective or harmful medication regimens.
Contention
Debates surrounding SB 959 are likely to revolve around the balance between cost control in prescription drug coverage and the need for patient-centered healthcare. Critics may argue that liberalizing access to override exceptions could drive up insurance costs and complicate the management of step therapy protocols. Supporters, however, contend that patient safety and effective treatment outcomes justify the need for these exceptions, particularly in cases where step therapy could otherwise delay necessary treatments.
Notable_points
Key aspects of the bill include mandates for health carriers to clearly disclose the override request process, as well as stipulations that request approvals must be based on documented medical evidence. Additionally, the bill excludes pharmacy drug samples from being counted as prior failures in step therapy, aiming to protect patients from unnecessary trials of ineffective medications.
Limits the use by insurers of step therapy, a protocol that establishes a specific sequence in which prescription drugs for a specified medical condition are covered by an insurer, by allowing medical providers to request step therapy exceptions.
Limits the use by insurers of step therapy, a protocol that establishes a specific sequence in which prescription drugs for a specified medical condition are covered by an insurer, by allowing medical providers to request step therapy exceptions.
Limits the use by insurers of step therapy, a protocol that establishes a specific sequence in which prescription drugs for a specified medical condition are covered by an insurer, by allowing medical providers to request step therapy exceptions.
Limits the use by insurers of step therapy, a protocol that establishes a specific sequence in which prescription drugs for a specified medical condition are covered by an insurer, by allowing medical providers to request step therapy exceptions.
Prescriptions for testosterone not allowed to be transmitted or reported within the prescription drug monitoring database and removes from the records all existing information concerning prior testosterone prescriptions.
Prescriptions for testosterone not allowed to be transmitted or reported within the prescription drug monitoring database and removes from the records all existing information concerning prior testosterone prescriptions.
Increases the maximum fill for non-opioid, non-narcotic controlled substances found in schedule II, so that a sixty-day (60) supply may be dispensed at any one time.
Increases the maximum fill for non-opioid, non-narcotic controlled substances found in schedule II, so that a ninety-day (90) supply may be dispensed at any one time.